基于免疫优势CD4+和CD8+ T细胞表位的新型寨卡疫苗开发
本研究在寨卡病毒短暂感染的小鼠中,通过覆盖病毒多蛋白全长的427条重叠肽进行表位定位,发现27个免疫优势表位。选取前10个表位组成三种T细胞疫苗,可诱导T细胞介导的细胞毒性和细胞因子产生,并对寨卡病毒攻击提供不同程度保护,还能增强中和抗体疫苗的保护效果。
要点
- 寨卡病毒感染小鼠中鉴定出27个免疫优势表位,分布于C、E、NS1-NS5蛋白。
- 其中8个为CD4+ T细胞表位,16个为CD8+ T细胞表位,3个为两者共有。
- 基于前10个表位的T细胞疫苗可诱导细胞免疫并增强抗体疫苗保护效果。
核心结论
- 寨卡病毒特异性CD4+和CD8+ T细胞具有保护作用,T细胞疫苗不诱导针对病毒表面的抗体, unlikely cause ADE,且可增强抗体诱导疫苗的效果。
研究设计与样本
- 在免疫健全的短暂感染寨卡病毒的小鼠中,使用427条重叠肽覆盖病毒多蛋白全长进行表位定位。
主要发现
- 发现27个免疫优势表位,其中8个CD4+ T细胞表位、16个CD8+ T细胞表位、3个两者共有。
- 选取前10个表位组成三种T细胞疫苗(CD4+表位、CD8+表位或两者混合),免疫后诱导T细胞介导的细胞毒性和细胞因子产生。
- 这些T细胞疫苗对寨卡病毒攻击提供不同程度保护,并提高中和抗体诱导的重组E80蛋白疫苗的保护效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zika virus (ZIKV) caused over two million human infections in more than 80 countries around 2015-2016. Current vaccines under development are mostly focused on inducing antibodies that despite capable of inhibiting the virus, may have the potential to trigger antibody dependent enhancement (ADE). T cell vaccines that do not induce antibodies targeting viral surface will unlikely cause ADE, but be capable of potentiating the effectiveness of an antibody-inducing vaccine. To develop such a protective T cell vaccine, we first examined the repertoire of antigen-specific T cells in immunocompetent mice that have been transiently infected by ZIKV. Through epitope mapping using 427 overlapping peptides spanning the entire length of ZIKV polyprotein, we discovered 27 immunodominant epitopes scattered throughout the virus on C, E, NS1-NS5 proteins. Among them, 8 were confirmed as CD4+ T cell epitopes, and 16 as CD8+ T cell epitopes, while 3 for both T cell subsets. From these 27 newly identified epitopes, the top 10 epitopes were selected to formulate three T cell vaccines comprised of either CD4+ T cell epitopes, or CD8+ T cell epitopes, or a mixture of both. Immunization with these T cell epitopes induced T cell-mediated cytotoxicity and cytokine production, and conferred varying degrees of protection against ZIKV challenge. Moreover, these new T cell vaccines also improved the protective efficacy of a neutralizing antibody-inducing recombinant E80 protein vaccine. Together, our results provided additional evidence in support of the protective role of ZIKV-specific CD4+ and CD8+ T cells, and laid foundation for future development of T cell vaccines for ZIKV.
引用
- Sun J, Zheng Z, Li M, et al. Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+ T cell epitopes identified through comprehensive epitope mapping in Zika virus infected mice. Vaccine. 2021. PMID: 34353682. doi:10.1016/j.vaccine.2021.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。